3 ASX Penny Stocks With Market Caps Under A$500M

As the Australian market grapples with rising oil prices and inflationary pressures, investors are navigating a challenging landscape that has seen the ASX 200 experience multiple consecutive losses. Amidst this backdrop, penny stocks—though an old term—remain a relevant area for those seeking potential opportunities in smaller or newer companies. These stocks can offer affordability and growth potential when backed by solid financials, making them worth exploring for hidden value in today's market conditions.

Here's a peek at a few of the choices from the screener.

Coast Entertainment Holdings (ASX:CEH)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Coast Entertainment Holdings Limited invests in and operates leisure and entertainment businesses in Australia, with a market cap of A$200.11 million.

Operations: The company's revenue is derived from its Theme Parks & Attractions segment, totaling A$116.47 million.

Market Cap: A$200.11M

Coast Entertainment Holdings has demonstrated a turnaround, achieving profitability with A$6.12 million net income for the year ending June 30, 2026. This marks a shift from a previous net loss and reflects an improvement in operational performance despite a significant one-off loss of A$128K impacting results. The company's revenue growth to A$117.92 million underscores its positive trajectory, supported by an experienced board and management team. With no debt on its balance sheet and short-term assets exceeding liabilities, Coast Entertainment is positioned with financial stability amidst the inherent volatility typical of smaller-cap stocks in the entertainment sector.

• Click to explore a detailed breakdown of our findings in Coast Entertainment Holdings' financial health report.
• Learn about Coast Entertainment Holdings' future growth trajectory here.

Immutep (ASX:IMM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Immutep Limited is a clinical-stage biotechnology company focused on developing LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia, with a market cap of A$82.53 million.

Operations: The company generates revenue primarily from its immunotherapy segment, amounting to A$19.93 million.

Market Cap: A$82.53M

Immutep Limited, a clinical-stage biotechnology company, remains focused on its LAG-3 immunotherapies despite being pre-revenue. Recent developments include the strategic focus on eftilagimod alfa (efti) for head and neck squamous cell carcinoma and soft tissue sarcoma, supported by FDA designations. The discontinuation of the TACTI-004 trial due to manufacturing inconsistencies highlights challenges in scaling production. Immutep's financials reveal an A$79.3 million net loss for FY 2026, with revenue at A$24.17 million but no meaningful shareholder dilution recently. Despite unprofitability and declining earnings forecasts, Immutep benefits from experienced management and a sufficient cash runway exceeding three years.

• Navigate through the intricacies of Immutep with our comprehensive balance sheet health report here.
• Explore Immutep's analyst forecasts in our growth report.

Jupiter Mines (ASX:JMS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Jupiter Mines Limited is an independent mining company based in Australia, with a market capitalization of A$491.46 million.

Operations: The company generates revenue of A$9.26 million from its manganese operations in South Africa.

Market Cap: A$491.46M

Jupiter Mines Limited, with a market cap of A$491.46 million, operates debt-free and has not diluted shareholders in the past year. Despite high-quality earnings and an experienced management team, its financial performance has seen declining trends; earnings have decreased by 9.8% annually over five years, with recent net profit margins lower than last year. The company's dividend yield of 5.2% is not well covered by free cash flow, though it maintains a stable weekly volatility at 4%. Recent financial results show slight declines in sales and net income compared to the previous year.

• Take a closer look at Jupiter Mines' potential here in our financial health report.
• Understand Jupiter Mines' track record by examining our performance history report.

Summing It All Up

• Unlock our comprehensive list of 393 ASX Penny Stocks by clicking here.
• Want To Explore Some Alternatives? We've found 7 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com